Effect of Different Antilipidemic Agents and Diets on Mortality. A Systematic Review

Basel Institute for Clinical Epidemiology, University Hospital Basel, CH-4031 Basel, Switzerland.
Archives of Internal Medicine (Impact Factor: 17.33). 05/2005; 165(7):725-30. DOI: 10.1001/archinte.165.7.725
Source: PubMed


Guidelines for the prevention and treatment of hyperlipidemia are often based on trials using combined clinical end points. Mortality data are the most reliable data to assess efficacy of interventions. We aimed to assess efficacy and safety of different lipid-lowering interventions based on mortality data.
We conducted a systematic search of randomized controlled trials published up to June 2003, comparing any lipid-lowering intervention with placebo or usual diet with respect to mortality. Outcome measures were mortality from all, cardiac, and noncardiovascular causes.
A total of 97 studies met eligibility criteria, with 137,140 individuals in intervention and 138,976 individuals in control groups. Compared with control groups, risk ratios for overall mortality were 0.87 for statins (95% confidence interval [CI], 0.81-0.94), 1.00 for fibrates (95% CI, 0.91-1.11), 0.84 for resins (95% CI, 0.66-1.08), 0.96 for niacin (95% CI, 0.86-1.08), 0.77 for n-3 fatty acids (95% CI, 0.63-0.94), and 0.97 for diet (95% CI, 0.91-1.04). Compared with control groups, risk ratios for cardiac mortality indicated benefit from statins (0.78; 95% CI, 0.72-0.84), resins (0.70; 95% CI, 0.50-0.99) and n-3 fatty acids (0.68; 95% CI, 0.52-0.90). Risk ratios for noncardiovascular mortality of any intervention indicated no association when compared with control groups, with the exception of fibrates (risk ratio, 1.13; 95% CI, 1.01-1.27).
Statins and n-3 fatty acids are the most favorable lipid-lowering interventions with reduced risks of overall and cardiac mortality. Any potential reduction in cardiac mortality from fibrates is offset by an increased risk of death from noncardiovascular causes.

Download full-text


Available from: Matthias Briel, Mar 18, 2014
59 Reads
  • Source
    • "They improve endothelial dysfunction and reduce the growth of atherosclerotic plaque [4]. Available evidence does not strongly suggest clear clinical benefit of other lipid-lowering agents in such situations [5]. All of the available statins have small differences in terms of pharmacokinetics and pharmacodynamics and hence in clinical efficacy and side effects profile [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Treatment of hyperlipidemia is helpful in both primary and secondary prevention of coronary heart disease and stroke. Aim. To compare lipid-lowering efficacy of rosuvastatin with atorvastatin. Methodology. This open-label randomized controlled trial was carried out at 1 Mountain Medical Battalion from September 2012 to August 2013 on patients with type 2 diabetes, hypertension, myocardial infarction, or stroke, meriting treatment with a statin. Those with secondary causes of dyslipidemia were excluded. Blood samples for estimation of serum total cholesterol, triglycerides, HDL-C, and LDL-C were collected after a 12-hour fast. Patients were randomly allocated to receive either atorvastatin 10 mg HS or rosuvastatin 5 mg HS daily. Lipid levels were rechecked after six weeks. Results. Atorvastatin was used in 63 patients and rosuvastatin in 66. There was a greater absolute and percent reduction in serum LDL-C levels with rosuvastatin as compared to atorvastatin (0.96 versus 0.54 mg/dL; P = 0.011 and 24.34 versus 13.66%; P = 0.045), whereas reduction in all other fractions was equal. Myalgias were seen in 5 (7.94%) patients treated with atorvastatin and 8 (12.12%) patients treated with rosuvastatin (P: 0.432). Conclusion. Rosuvastatin produces a greater reduction in serum LDL-C levels and should therefore be preferred over atorvastatin.
    03/2014; 2014(5):875907. DOI:10.1155/2014/875907
  • Source
    • "Polyamides, poly (amino acids), poly (alkyl-α-cyano acrylates), polyesters, poly orthoesters, polyurethanes and polyacrylamides have been used to set up different drug-loaded devices (Jain, 2000; Lü et al., 2009; Panyam and Labhasetwar, 2012) between them, the thermoplastic aliphatic polyesters, like polylactic acid, poly glycolic acid and specially the copolymer poly (lactic co-glycolic acid) (PLGA), have a long history of use as biomaterials because of their exceptional biocompatibility and biodegradability. (Studer et al., 2005; Wickline et al., 2007; Lü et al., 2009). Langer and Folkman were the first to demonstrate the controlled release of macromolecules via polymers, which facilitated the development of antiangiogenic drug delivery systems for cancer therapy and opened up novel areas for the delivery of macromolecules (Langer and Folkman, 1976; Dinarvand et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Poly (lactic-co-glycolic acid) (PLGA) is one of the most effective biodegradable polymeric nanoparticles (NPs). It has been approved by the US FDA to use in drug delivery systems due to controlled and sustained- release properties, low toxicity, and biocompatibility with tissue and cells. In the present review, the structure and properties of PLGA copolymers synthesized by ring-opening polymerization of DL-lactide and glicolide were characterized using 1H nuclear magnetic resonance spectroscopy, gel permeation chromatography, Fourier transform infrared spectroscopy and differential scanning calorimetry. Methods of preparation and characterization, various surface modifications, encapsulation of diverse anticancer drugs, active or passive tumor targeting and different release mechanisms of PLGA nanoparticles are discussed. Increasing experience in the application of PLGA nanoparticles has provided a promising future for use of these nanoparticles in cancer treatment, with high efficacy and few side effects.
    Asian Pacific journal of cancer prevention: APJCP 01/2014; 15(2):517-535. DOI:10.7314/APJCP.2014.15.2.517 · 2.51 Impact Factor
  • Source
    • "However, it is becoming increasingly clear that the Framingham score is based on risk factors, which may not be causal. For example the causal role of HDL-cholesterol in IHD has been challenged in several recent studies of different designs [40], [41], [42], suggesting HDL-cholesterol predicts well as an indicator of some other underlying factor. Notably, androgens generate unfavourable levels of HDL-cholesterol [43], however there could be many other potential factors which lower HDL-cholesterol and cause IHD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: With economic development and population aging, ischaemic heart disease (IHD) is becoming a leading cause of mortality with widening inequalities in China. To forewarn the trends in China we projected IHD trends in the most economically developed part of China, i.e., Hong Kong. Based on sex-specific IHD mortality rates from 1976 to 2005, we projected mortality rates by neighborhood-level socio-economic position (i.e., low- or high-income groups) to 2020 in Hong Kong using Poisson age-period-cohort models with autoregressive priors. In the low-income group, age-standardized IHD mortality rates among women declined from 33.3 deaths in 1976-1980 to 19.7 per 100,000 in 2016-2020 (from 55.5 deaths to 34.2 per 100,000 among men). The rates in the high-income group were initially higher in both sexes, particularly among men, but this had reversed by the end of the study periods. The rates declined faster for the high-income group than for the low-income group in both sexes. The rates were projected to decline faster in the high-income group, such that by the end of the projection period the high-income group would have lower IHD mortality rates, particularly for women. Birth cohort effects varied with sex, with a marked upturn in IHD mortality around 1945, i.e., for the first generation of men to grow up in a more economically developed environment. There was no such upturn in women. Birth cohort effects were the main drivers of change in IHD mortality rates. IHD mortality rates are declining in Hong Kong and are projected to continue to do so, even taking into account greater vulnerability for the first generation of men born into a more developed environment. At the same time social disparities in IHD have reversed and are widening, partly as a result of a cohort effect, with corresponding implications for prevention.
    PLoS ONE 04/2013; 8(4):e61495. DOI:10.1371/journal.pone.0061495 · 3.23 Impact Factor
Show more